|
|
Volumn 2, Issue 2, 2005, Pages 70-71
|
|
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
a
a
|
|
Author keywords
Androgen independent; Docetaxel; Estramustine; Prostate cancer; Survival
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTIANDROGEN;
CORTICOSTEROID;
DEXAMETHASONE;
DOCETAXEL;
ESTRAMUSTINE PHOSPHATE SODIUM;
GONADORELIN AGONIST;
MITOXANTRONE;
NAVELBINE;
PREDNISONE;
PROSTATE SPECIFIC ANTIGEN;
WARFARIN;
ANALGESIA;
ANTINEOPLASTIC ACTIVITY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GROWTH;
CANCER HORMONE THERAPY;
CANCER MORTALITY;
CANCER PAIN;
CANCER SURVIVAL;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
CONFIDENCE INTERVAL;
DIARRHEA;
DOSE CALCULATION;
DRUG DOSE REGIMEN;
DRUG FATALITY;
DRUG POTENTIATION;
DRUG RESPONSE;
DRUG WITHDRAWAL;
FATIGUE;
FEBRILE NEUTROPENIA;
FOLLOW UP;
HUMAN;
LIFE EXPECTANCY;
MALE;
METABOLIC DISORDER;
METASTASIS;
NAUSEA AND VOMITING;
NEUROLOGIC DISEASE;
NEUROPATHY;
NEUTROPENIA;
PERIPHERAL EDEMA;
PRIORITY JOURNAL;
PROGNOSIS;
PROSPECTIVE STUDY;
PROSTATE ADENOCARCINOMA;
PROTEIN BLOOD LEVEL;
QUALITY OF LIFE;
SHORT SURVEY;
SIDE EFFECT;
SURVIVAL TIME;
THROMBOEMBOLISM;
TREATMENT FAILURE;
VASCULAR DISEASE;
ADENOCARCINOMA;
AGED;
ANDROGENS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ESTRAMUSTINE;
HUMANS;
INFUSIONS, INTRAVENOUS;
MALE;
MITOXANTRONE;
PREDNISONE;
PROSPECTIVE STUDIES;
PROSTATIC NEOPLASMS;
SURVIVAL ANALYSIS;
TAXOIDS;
TREATMENT OUTCOME;
|
|
EID: 20344371442
PISSN: 17434254
EISSN: None
Source Type: Journal
DOI: 10.1038/ncponc0076 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (6)
|
